Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CoAxia Inc.

This article was originally published in Start Up

Executive Summary

CoAxia Inc. has a new approach to neuroprotection for ischemic stroke: by partially restricting blood flow in the lower body, it diverts a larger portion of cardiac output into the cerebral vasculature to perfuse the penumbra, keeping those cells viable until circulation is restored. CoAxia believes its technology is simple, safe, and will dramatically expand the treatment window for ischemic stroke patients.

You may also be interested in...



BeneChill Inc.

Lowering brain temperature protects cerebral tissue from ischemic damage, but any delay in inducing hypothermia compromises patient outcomes. BeneChill Inc. noninvasively delivers PFCs to the nose, and the resulting rapid heat exchange selectively cools the brain. The company will design a device for in-hospital use, as well as a version that can be used by first responders in the field.

BeneChill Inc.

Lowering brain temperature protects cerebral tissue from ischemic damage, but any delay in inducing hypothermia compromises patient outcomes. BeneChill Inc. noninvasively delivers PFCs to the nose, and the resulting rapid heat exchange selectively cools the brain. The company will design a device for in-hospital use, as well as a version that can be used by first responders in the field.

Persistently Seeking Stroke Solutions

Even as ischemic stroke researchers debate what went wrong following a string of high-profile, expensive clinical trial failures, they're optimistic that advances in understanding of the disease and application of lessons learned from past mistakes will yield more effective therapies.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

MT037299

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel